Bio News
GLP-1 concentration intensifies, posing a fundamental threat to R&D productivity Average development cost reaches $2.67 billion, up 19.8% from the previous year
As drug development costs rose 19.8%, obesity treatments surpassed oncology drugs to rank first in pipeline value. The internal rate of return (IRR) for R&D plunged from 7.0% to 2.9% as investment concentrated in GLP-1 drugs. Going forward, the top three companies are expected to hold 95% of the obesity market’s value, intensifying market concentration.
Biobook Team
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
